Sector: MedicalXOMA Ltd. (NASDAQ: XOMA)
Headlines
- XOMA Appoints Jim Neal Vice President of Business Development
Nov 17, 2009 08:02 AM | XOMA
- XOMA 052 Selected as a Top Ten Project to Watch
Nov 12, 2009 03:18 PM | ENL, XOMA
- XOMA Announces Presentation at Lazard Healthcare Conference on November 18
Nov 11, 2009 02:31 PM | XOMA
- XOMA Reports 2009 Third Quarter Financial Results
Nov 09, 2009 08:01 AM | XOMA
- XOMA Expands Development Strategy for XOMA 052 to Include Cardiovascular Diseases
Nov 06, 2009 08:01 AM | XOMA
- Phase 2 Trial of XOMA 052 to be Initiated in Type 1 Diabetes Patients
Nov 04, 2009 08:05 AM | XOMA
- XOMA Granted First European Patent Covering XOMA 052
Nov 04, 2009 08:04 AM | XOMA
- XOMA to Announce Third Quarter 2009 Financial Results and Host Conference Call on November 9
Nov 03, 2009 05:23 PM | XOMA
- Dr. Stockpick Announces Daily Stock Watch - XOMA, DDRX, CEPH
Nov 03, 2009 10:05 AM | CEPH, PEET, XOMA
- XOMA Signs Antibody Discovery Collaboration With Kaketsuken
Nov 03, 2009 08:03 AM | XOMA
- XOMA Receives NASDAQ Determination Letter
Nov 19, 2009 05:14 PM | XOMA
- RidgewaterEquity.com Free Fundamental Sector & Market Research on SAH, WR, RTP, YSI, TSO and XOMA
Nov 04, 2009 06:08 AM | RTP, SAH, TSO, WR, XOMA, YSI
- BenchmarkJournal.Com Free Analyst Review for VPRT, ARCC, STAR, VRNM, XOMA and SVNT
Aug 26, 2009 07:11 AM | ARCC, STAR, SVNT, VPRT, VRNM, XOMA
- XOMA to Present At Canaccord Adams Global Growth Conference On August 12, 2009
Aug 10, 2009 04:26 PM | XOMA
- XOMA Reports 2009 Second Quarter Financial Results
Aug 06, 2009 04:06 PM | XOMA
- XOMA to Announce Second Quarter 2009 Financial Results and Host Conference Call on August 6
Aug 03, 2009 04:02 PM | XOMA
- XOMA Announces New U.S. Government Biodefense Subcontract for Development of Therapeutic Antibodies to Treat SARS
Jul 30, 2009 07:01 AM | XOMA
- XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes
Jul 14, 2009 04:28 PM | XOMA
- XOMA Announces Conference Call and Webcast On July 14 to Review Top Line Multi-dose and Other Results of Its Phase 1 Clinical Trial of XOMA 052 in Type 2 Diabetes
Jul 07, 2009 07:02 AM | XOMA
- XOMA Presents Data At ADA Demonstrating Improvement in Diabetes and Inflammatory Measures in Animal Model With XOMA 052
Jun 08, 2009 04:25 PM | XOMA
- Form 4 XOMA LTD /DE/ For: Nov 10 Filed by: VAN NESS W DENMAN (10K)
Nov 12, 2009 05:23 PM
- Form 4 Varian John For: May 21 (10K)
Jun 08, 2009 08:49 PM
- Form 4 HUTT PETER BARTON For: May 21 (10K)
May 21, 2009 09:02 PM
- Form 4 XOMA LTD /DE/ For: May 21 Filed by: ZENNER PATRICK J (10K)
May 21, 2009 09:01 PM
- Form 4 VAN NESS W DENMAN For: May 21 (10K)
May 21, 2009 09:01 PM
- Form 4 BOWES WILLIAM K JR For: May 21 (10K)
May 21, 2009 08:59 PM
- Form 4 MARGOLIN CHRISTOPHER J For: Feb 26 (10K)
Mar 02, 2009 05:40 PM
- Form 4 KURLAND FRED For: Feb 26 (10K)
Mar 02, 2009 05:38 PM
- Form 4 ENGLE STEVEN B For: Feb 26 (10K)
Mar 02, 2009 05:38 PM
- Form 4 SCANNON PATRICK J MD For: Feb 26 (10K)
Mar 02, 2009 05:37 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
XOMA
|
Compare to S&P
|
| YTD |
19.19 %
|
-1.35 %
|
| 4 Weeks |
-3.41 %
|
-4.45 %
|
| 12 Weeks |
-14.07 %
|
-18.99 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 114.29 %
|
|
EPS Growth in Last Year: 106.67 %
|
|
Sales Growth in Last Quarter: 202.15 %
|
|
Sales Growth in Last Quarter: 247.39 %
|
|
